Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to B/F/TAF in Virologically Suppressed HIV-1
NCT02603120Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2015
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of bictegravir in human immunodeficiency virus type 1 infection (HIV-1) (3 arms), sponsored by Gilead Sciences. Primary endpoint: Percentage of Participants With Virologic Failure (HIV-1 RNA >= 50 Copies/mL) at 48 weeks. Started Nov 2015; status: completed.
02
Drugs
bictegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02603120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02603120.